Communiqués AstraZeneca PLC Buenos Aires S.E.

Actions

AZN

ARDEUT112489

Produits pharmaceutiques

Cours en clôture Buenos Aires S.E. 17/09/2026			Varia. 5j.	Varia. 1 janv.
66 100,00 ^ARS	+1,58 %		+5,51 %	-6,31 %

17/09	Les indices FTSE progressent après le maintien des taux de la BoE et la suspension des ventes de gilts	RE
17/09	Les bourses européennes clôturent en hausse jeudi ; l'inflation progresse dans l'UE en août ; la Banque d'Angleterre maintient ses taux	MT

Communiqués

14/09	ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial	BU
14/09	TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial	BU
11/09	AstraZeneca : Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer	PU
08/09	IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer	BU
08/09	Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials	BU
08/09	AstraZeneca : Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials	PU
05/09	ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer	BU
04/09	AstraZeneca : Etcamah in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer	PU
01/09	AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer	BU
01/09	AstraZeneca : Enhertu plus pertuzumab approved in the EU as first new regimen in more than a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer	PU
01/09	AstraZeneca : completes global license agreement for oral EGFR inhibitor Zegfrovy for lung cancer	PU
27/08	TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints	BU
20/08	Foresite Labs Appoints Dr. Jorge Reis-Filho to Chief Strategy Officer and Operating Partner; Joins Foresite Capital as Venture Partner	AQ
18/08	AstraZeneca - Update on eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer	AQ
17/08	ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial	BU
17/08	TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO	BU
17/08	HUTCHMED Announces ORPATHYS plus TAGRISSO Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer	AQ
17/08	AstraZeneca : Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial	PU
17/08	AstraZeneca : Update on eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer	PU
04/08	BITTER PILL TO SWALLOW?	AQ
27/07	Beyond De-risking: How European Companies Can Develop New Technologies In China	AQ
27/07	Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers	BU
27/07	AstraZeneca results: H1 and Q2 2026	BU
27/07	Astrazeneca: Q2 Earnings Snapshot	AQ
27/07	AstraZeneca : Update on Phase III trial of Ultomiris in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplant	PU